Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging

Author(s): S.C. Ghosh, A. Azhdarinia

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 29 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Multimodal imaging agents were first introduced a decade ago and consist of a targeting moiety that is dual-labeled with radioactive and fluorescent contrast. These compounds allow whole-body and intraoperative imaging to be performed through administration of a single agent and provide complementary diagnostic information that can be used to guide tumor resection. Since their initial evaluation, interest in dual-labeled agents has continued to grow and their design has subsequently evolved alongside the development of novel chelating agents, improved fluorophores, and highly selective coupling techniques for bioconjugate formation. In this review, will discuss how changes in the labeling components and schemes for multimodal agent development have impacted imaging performance and will focus on antibody- and peptide-based agents as models for dual labeling. We will also describe the growing role of modular dual labeling strategies as well as direct labeling methods using radiohalogens.

Keywords: Dual labeling, molecular imaging, multimodality, near-infrared fluorescence, radioisotope, nuclear imaging.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 29 September, 2015
Page: [3390 - 3404]
Pages: 15
DOI: 10.2174/0929867322666150904111214
Price: $65

Article Metrics

PDF: 47
PRC: 1